Mapping GLP-1 game plans; Q2 earnings highlights; J&J vets regroup at...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleAstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 chronic...
When given with other cancer drugs for a limited time, AstraZeneca’s Calquence hit the primary endpoint in a registrational test, which could open up a bigger opportunity for the blockbuster drug in...
View ArticleClik here to view.
Updated: GSK and Flagship to create up to 10 vaccines, medicines across...
GSK and Flagship Pioneering will jointly pay up to $150 million to kick-start a respiratory and immunology tie-up. The pair will create new vaccines and medicines based on work out of Flagship’s...
View ArticleWuXi AppTec sees US revenue decline amid Biosecure threat
WuXi AppTec saw a slight drop in revenue and a bigger fall in profit in the first half of 2024, with US revenue dipping as the company remains a political target for American lawmakers. Despite the...
View ArticleNewAmsterdam succeeds in the first of three key pivotal studies, providing...
NewAmsterdam Pharma aced the first in a cascade of Phase 3 readouts, showing that its lead cardio medicine took down levels of bad cholesterol. The positive results, if they bear out in future...
View ArticleCollegium pays $525M to buy ADHD company; FDA delays Syndax decision
Plus, news about Cipher, ParaPRO, Viracta, ReviR Therapeutics and Luye Pharma: Collegium’s $525M acquisition: The pain biotech plans to pay that amount, plus a potential $25 million in commercial...
View ArticleClik here to view.
#AAIC24: Cognition Therapeutics' stock sinks on Phase 2 Alzheimer’s data
New Alzheimer’s data from Cognition Therapeutics appeared to show an early drug effect, but one that lessened over time. Cognition presented Phase 2 results from two dose cohorts comparing its oral...
View ArticleVentyx axes development of TYK2 inhibitor following Phase 2 failure
Ventyx Biosciences is shelving a drug after a mid-stage miss and failure. The company was investigating VTX958, an allosteric TYK2 inhibitor, in patients with moderately to severely active Crohn’s...
View ArticleClik here to view.
Boehringer Ingelheim buys oncology biotech Nerio Therapeutics for up to $1.3B
Boehringer Ingelheim is paying up to $1.3 billion to acquire a relatively unknown immuno-oncology biotech out of La Jolla, CA. The German drug giant said Monday morning it will buy preclinical-stage...
View ArticleFDA's ad enforcer critiques Brittany Mahomes' paid Instagram post for Kaléo
Brittany Mahomes’ Instagram is the subject of a recent letter the FDA sent to Kaléo regarding a misleading direct-to-consumer ad for its epinephrine injection. The FDA called the Instagram post and...
View ArticlePfizer cuts 210 North Carolina workers after it officially discontinues...
Pfizer will end development on its experimental Duchenne muscular dystrophy gene therapy after a Phase 3 failure last month, and plans to eliminate roles at a North Carolina site that was working on...
View ArticleClik here to view.
Roivant's dealmaker lands $81M cash bonus following drug sale to Roche
One of the best pharma deals in recent history has now led to one of the industry’s biggest-ever executive paydays. Roivant awarded its top dealmaker Mayukh Sukhatme an $80.55 million cash bonus,...
View ArticleIndivior reaches $86M settlement over its alleged role in the opioid epidemic
Indivior will pay $86 million over five years as part of a settlement with 17 states over it’s alleged role in the opioid epidemic, New York Attorney General Letitia James announced last week....
View ArticleAstraZeneca and Daiichi Sankyo fail to win NICE recommendation for Enhertu,...
The United Kingdom’s drug pricing watchdog has officially declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu for HER2-low breast cancer in the UK, noting that the companies were “unwilling”...
View ArticleBessemer VC Morgan Cheatham shares how AI healthcare startups can win in a...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Among what seems like a gazillion startups using AI to solve administrative problems for healthcare...
View ArticleClik here to view.
Roche begins Phase 2 obesity trial for GLP-1/GIP agonist CT-388
Roche said it would step on the gas pedal to catch up to Novo Nordisk and Eli Lilly (plus many other hopefuls) in obesity. And it has. The Swiss pharma conglomerate has kicked off a Phase 2 trial of...
View ArticleKeytruda tops $7B quarterly sales for the first time
Merck’s Keytruda has a new line on its long list of accomplishments: topping $7 billion in quarterly sales for the first time. On Tuesday, the New Jersey drugmaker said the cancer drug’s quarterly...
View ArticleClik here to view.
Montara Therapeutics, co-founded by UCSF's Kevan Shokat, to develop new neuro...
A year after selling their first neuro startup to AbbVie, Kevan Shokat and the former PhD student he co-founded that company with are back with a new idea. Montara Therapeutics is starting small with...
View ArticleCelldex says barzolvolimab scores in Phase 2 test in chronic inducible urticaria
Celldex said its monoclonal antibody has shown encouraging efficacy in a mid-stage trial in patients with an inflammatory skin condition that features hives and swelling, setting the stage for...
View ArticleClik here to view.
Pfizer ups 2024 guidance by $1B after multiple rounds of cost cuts
Pfizer beat Wall Street’s expectations on revenue in the second quarter and raised its full-year revenue guidance by $1 billion, it said Tuesday morning. The large drugmaker pulled in $13.3 billion...
View Article